New York University professor Scott Galloway suggests investors pivot from volatile high-profile IPOs toward the pharmaceutical sector, specifically targeting companies producing GLP-1 receptor agonists. Following SpaceX’s June 12 IPO, which saw shares fluctuate, Galloway argued in a June 17 Medium post that market demand for the space company is artificially inflated. Instead, he highlights GLP-1 weight-loss drugs as a more sustainable long-term investment due to their expanding medical applications and consistent user retention rates.
Why is Scott Galloway skeptical of the recent SpaceX IPO?
Galloway contends that the $75 billion valuation placed on SpaceX does not reflect its fundamental business value. According to his June 17 Medium post, the company’s ability to secure a waiver from Nasdaq requirements allowed it to force index funds to purchase shares, creating a “demand cannon” for a stock with a relatively small float. This mechanism, he argues, creates a trade rather than a traditional investment opportunity. Reuters reports that shares began dropping shortly after the initial market activity, reinforcing concerns about the stability of the price.
GLP-1 drugs were originally approved for diabetes management, but their efficacy in treating obesity, addiction, and sleep apnea has significantly broadened their market potential, according to Scott Galloway.
How does Eli Lilly compare to Novo Nordisk in the GLP-1 market?
Eli Lilly has emerged as a dominant force in the GLP-1 space, outpacing competitors like Novo Nordisk. Data from Eli Lilly’s historic price lookup shows the company’s stock grew from $276.22 at the end of 2021 to $1,074.68 by the end of 2025—a 418% increase. Galloway attributes this success to aggressive direct-to-consumer marketing strategies. Eli Lilly CEO David Ricks noted that the company views its pricing as elastic, meaning lower price points correlate with higher user adoption, a strategy the company is actively pursuing to maintain its market lead.
What are the primary barriers to GLP-1 adoption?
Despite the medical potential of GLP-1s, cost remains the most significant hurdle for widespread access. The Cleveland Clinic reports that the high monthly cost, often reaching hundreds of dollars, forces many patients to discontinue treatment. Furthermore, insurance coverage for these drugs is increasingly restrictive, according to NPR. While Eli Lilly has implemented programs—such as a $50 monthly cap for Medicaid D beneficiaries and self-pay options for the uninsured—costs can still reach $449 per multi-dose pen for those without coverage.
When evaluating pharmaceutical stocks, look for companies with active pipelines. Eli Lilly is currently conducting phase 3 trials on a new combination drug, which analysts suggest could provide further upside to the company’s valuation if successful.
Frequently Asked Questions
Are GLP-1 drugs considered a long-term investment?
According to Scott Galloway, GLP-1s function similarly to a subscription service because patients tend to remain on the medication for extended periods, creating recurring revenue for manufacturers like Eli Lilly.
Why is insurance coverage for weight-loss drugs inconsistent?
Insurance providers often limit coverage for GLP-1s due to the high monthly price of the drugs, which can cost hundreds of dollars per patient, as reported by the Cleveland Clinic and NPR.
What is the status of Eli Lilly’s drug pipeline?
The company is currently developing a new combination GLP-1 medication that has shown promising results in phase 3 clinical trials, according to company records.
This article provides information only and should not be construed as financial advice. Always conduct your own research before making investment decisions.
Want more insights on market trends and sector analysis? Subscribe to our weekly newsletter to get the latest updates delivered directly to your inbox.